You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫藥(600056.SH):子公司醋酸阿託西班注射液(5ml、0.9ml)獲得藥品註冊證書
格隆匯 01-28 18:14

格隆匯1月28日丨中國醫藥(600056.SH)公佈,近日,中國醫藥健康產業股份有限公司下屬全資子公司海南通用三洋藥業有限公司(“通用三洋”)收到國家藥品監督管理局核准簽發的兩份醋酸阿託西班注射液(簡稱“該藥品”)《藥品註冊證書》。相關規格:5ml:37.5mg、0.9ml:6.75mg。

截至公吿披露日,通用三洋在該藥品研發項目上已累計投入約1700萬元(未經審計)。

該藥品主要用於預防早產,降低子宮的收縮頻率和張力,有效減少子宮收縮和延遲早產。

醋酸阿託西班注射液是由輝凌瑞士製藥有限公司研製的一種注射用催產素拮抗劑,於2000年4月在奧地利首次上市,是唯一具有子宮特異性的宮縮抑制劑。2006年5月輝凌瑞士製藥有限公司首次將醋酸阿託西班注射液進口到中國,商品名為依保(Tractocile),規格為5ml:7.5mg/ml(以阿託西班計)和0.9ml:7.5mg/ml(以阿託西班計)。

根據PDB數據庫國內市場樣本醫院用藥銷售統計顯示,該藥品2020年樣本醫院銷售總額約為9100萬元,2021年約為9500萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account